Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.

Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T, Yaghmaie M, Dörge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK.

Blood. 2012 Jul 12;120(2):395-403. doi: 10.1182/blood-2012-01-403220. Epub 2012 May 30.

2.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
3.

GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.

Hou HA, Lin YC, Kuo YY, Chou WC, Lin CC, Liu CY, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.

Ann Hematol. 2015 Feb;94(2):211-21. doi: 10.1007/s00277-014-2208-8. Epub 2014 Sep 21.

PMID:
25241285
4.

GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.

Green CL, Tawana K, Hills RK, Bödör C, Fitzgibbon J, Inglott S, Ancliff P, Burnett AK, Linch DC, Gale RE.

Br J Haematol. 2013 Jun;161(5):701-5. doi: 10.1111/bjh.12317. Epub 2013 Apr 5.

PMID:
23560626
5.

Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.

Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group.

Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24.

PMID:
22362118
6.

CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.

Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S.

Br J Haematol. 2013 Jun;161(5):649-58. doi: 10.1111/bjh.12297. Epub 2013 Mar 25.

PMID:
23521373
7.

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.

Fasan A, Eder C, Haferlach C, Grossmann V, Kohlmann A, Dicker F, Kern W, Haferlach T, Schnittger S.

Leukemia. 2013 Feb;27(2):482-5. doi: 10.1038/leu.2012.174. Epub 2012 Jul 3. No abstract available.

PMID:
22814295
8.

Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.

Fos J, Pabst T, Petkovic V, Ratschiller D, Mueller BU.

Blood. 2011 May 5;117(18):4881-4. doi: 10.1182/blood-2010-11-320747. Epub 2011 Mar 9.

9.

ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.

Damm F, Wagner K, Görlich K, Morgan M, Thol F, Yun H, Delwel R, Valk PJ, Löwenberg B, Heuser M, Ganser A, Krauter J.

Br J Haematol. 2012 Jul;158(2):208-15. doi: 10.1111/j.1365-2141.2012.09144.x. Epub 2012 May 9.

PMID:
22568493
10.

Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.

Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU.

J Clin Oncol. 2008 Nov 1;26(31):5088-93. doi: 10.1200/JCO.2008.16.5563. Epub 2008 Sep 2.

PMID:
18768433
11.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

12.

Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.

Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-McIver A, Arch R, Amess JA, Rohatiner AZ, Lister TA, Fitzgibbon J.

Genes Chromosomes Cancer. 2003 May;37(1):72-8.

PMID:
12661007
13.

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R.

Blood. 2009 Mar 26;113(13):3088-91. doi: 10.1182/blood-2008-09-179895. Epub 2009 Jan 26.

14.

Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.

Ping N, Sun A, Song Y, Wang Q, Yin J, Cheng W, Xu Y, Wen L, Yao H, Ma L, Qiu H, Ruan C, Wu D, Chen S.

Leukemia. 2017 Jan;31(1):195-202. doi: 10.1038/leu.2016.162. Epub 2016 Jun 15.

PMID:
27389056
15.

Complexity of CEBPA dysregulation in human acute myeloid leukemia.

Pabst T, Mueller BU.

Clin Cancer Res. 2009 Sep 1;15(17):5303-7. doi: 10.1158/1078-0432.CCR-08-2941. Epub 2009 Aug 25. Review.

16.

Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.

Tominaga-Sato S, Tsushima H, Ando K, Itonaga H, Imaizumi Y, Imanishi D, Iwanaga M, Taguchi J, Fukushima T, Yoshida S, Hata T, Moriuchi Y, Kuriyama K, Mano H, Tomonaga M, Miyazaki Y.

Int J Hematol. 2011 Jul;94(1):81-9. doi: 10.1007/s12185-011-0883-y. Epub 2011 Jun 16. Erratum in: Int J Hematol. 2012 Aug;96(2):291-2.

PMID:
21674360
17.

Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.

Li HY, Deng DH, Huang Y, Ye FH, Huang LL, Xiao Q, Zhang B, Ye BB, Lai YR, Mo ZN, Liu ZF.

Eur J Haematol. 2015 May;94(5):439-48. doi: 10.1111/ejh.12450. Epub 2015 Jan 22.

PMID:
25227715
18.

Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.

Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF.

Clin Cancer Res. 2005 Feb 15;11(4):1372-9.

19.

Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.

Benthaus T, Schneider F, Mellert G, Zellmeier E, Schneider S, Kakadia PM, Hiddemann W, Bohlander SK, Feuring-Buske M, Braess J, Spiekermann K, Dufour A.

Br J Haematol. 2008 Oct;143(2):230-9. doi: 10.1111/j.1365-2141.2008.07328.x. Epub 2008 Aug 24.

PMID:
18752591
20.

K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).

Carnicer MJ, Lasa A, Buschbeck M, Serrano E, Carricondo M, Brunet S, Aventin A, Sierra J, Di Croce L, Nomdedeu JF.

Ann Hematol. 2008 Oct;87(10):819-27. doi: 10.1007/s00277-008-0528-2. Epub 2008 Jun 28.

PMID:
18587575

Supplemental Content

Support Center